Holen Sie sich die Stockscreener-App
3.39
3.35%
0.11
Handel nachbörslich:
3.39
Schlusskurs vom Vortag:
$3.28
Offen:
$3.28
24-Stunden-Volumen:
719.27K
Relative Volume:
0.72
Marktkapitalisierung:
$254.60M
Einnahmen:
$6.96M
Nettoeinkommen (Verlust:
$-46.51M
KGV:
-19.76
EPS:
-0.1716
Netto-Cashflow:
$-37.99M
1W Leistung:
-11.02%
1M Leistung:
+41.84%
6M Leistung:
+2.42%
1J Leistung:
-67.68%
1-Tages-Spanne:
$3.26
$3.53
1-Wochen-Bereich:
$3.21
$3.90
52-Wochen-Spanne:
$1.60
$16.55
Perspective Therapeutics Inc Stock (CATX) Company Profile
Firmenname
Perspective Therapeutics Inc
Sektor
Branche
Telefon
509-375-1202
Adresse
350 Hills Street, Suite 106, Richland
Vergleichen Sie CATX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
3.39 | 254.60M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
134.11 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
103.63 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
391.81 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
88.28 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.02 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-11-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-01 | Eingeleitet | Wedbush | Outperform |
| 2024-09-25 | Eingeleitet | Truist | Buy |
| 2024-07-25 | Eingeleitet | BofA Securities | Buy |
| 2024-05-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Perspective Therapeutics Inc Aktie (CATX) Neueste Nachrichten
Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Rating of “Buy” from Analysts - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Bank of America Corp DE - Defense World
Analyzing Ratios: Perspective Therapeutics Inc (CATX)’s Financial Story Unveiled - DWinneX
The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic - insights.citeline.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Cantor Fitzgerald Forecasts CATX FY2026 Earnings - Defense World
Ameriprise Financial Inc. Sells 645,170 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
151,610 Shares in Perspective Therapeutics, Inc. (NYSE:CATX) Acquired by Two Sigma Advisers LP - Defense World
ProShare Advisors LLC Acquires 5,011 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics (NYSE:CATX) Rating Increased to Moderate Buy at Royal Bank of Canada - Defense World
Perspective Therapeutics (CATX) Price Target Raised by RBC Capital | CATX Stock News - GuruFocus
Perspective Therapeutics (CATX) Gets a Buy from Scotiabank - The Globe and Mail
RBC Capital Boosts Price Target for Perspective Therapeutics (CA - GuruFocus
Perspective Therapeutics Updates on Radiopharmaceutical Advancements - TipRanks
RBC Capital raises Perspective Therapeutics stock price target to $16 By Investing.com - Investing.com Nigeria
RBC Raises Price Target on Perspective Therapeutics to $16 From $15, Keeps Outperform, Speculative Risk - marketscreener.com
RBC Capital raises Perspective Therapeutics stock price target to $16 - Investing.com
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Nuveen Asset Management LLC - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Acquired by Deutsche Bank AG - Defense World
Two Sigma Investments LP Takes $2.08 Million Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics, Inc. (CATX) Reports Positive Results for NET Treatment Trial - Insider Monkey
Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-?-NET at the 2025 ASCO Annual Meeting | CATX Stock News - GuruFocus
Perspective Therapeutics Provides Updated Interim Results and Safety Findings for [212Pb]VMT-α-NET at ASCO 2025 - Nasdaq
Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting - The Manila Times
Millennium Management LLC Buys New Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Neuroendocrine Tumors Market: Epidemiology, Therapies, - openPR.com
Perspective Therapeutics Announces Voting Results By Investing.com - Investing.com Canada
Perspective Therapeutics Holds Annual Stockholders Meeting - TipRanks
Perspective Therapeutics Announces Voting Results - Investing.com
Northern Trust Corp Acquires 13,115 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Janus Henderson Group PLC Has $57,000 Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Given Consensus Rating of “Buy” by Brokerages - Defense World
HC Wainwright Has Pessimistic Outlook of CATX Q3 Earnings - Defense World
Equities Analysts Offer Predictions for CATX Q1 Earnings - Defense World
Perspective Therapeutics, Inc. (CATX): Analysts See 460% Upside Potential - MSN
Head-To-Head Review: Avinger (NASDAQ:AVGR) and Perspective Therapeutics (NYSE:CATX) - Defense World
Perspective Therapeutics’ SWOT analysis: rare disease stock faces clinical hurdles - Investing.com Nigeria
Mercer Global Advisors Inc. ADV Invests $51,000 in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics Reports Q1 2025 Earnings - TipRanks
Perspective Therapeutics (CATX) Rating Maintained, Price Target Lowered | CATX Stock News - GuruFocus
Truist Securities Adjusts Perspective Therapeutics Price Target to $8 From $10, Maintains Buy Rating - marketscreener.com
Oppenheimer cuts CATX stock price target to $15, maintains Outperform By Investing.com - Investing.com South Africa
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results | CATX Stock News - GuruFocus
Oppenheimer Trims Perspective Therapeutics Price Target to $15 From $16, Maintains Outperform Rating - marketscreener.com
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Acquired by Wells Fargo & Company MN - Defense World
Oppenheimer cuts CATX stock price target to $15, maintains Outperform - Investing.com
Perspective Therapeutics: Q1 Earnings Snapshot - The Washington Post
Perspective Therapeutics Inc (CATX) Q1 2025 Earnings: EPS Loss of $0.25 Beats Estimate, Revenue of $0.3M Exceeds Expectations - GuruFocus
Perspective Therapeutics Reports Q1 2025 Results and Updates - TipRanks
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results - The Manila Times
Perspective Therapeutics, Inc. Announces Clinical Updates and Recruitment Progress for Novel Radiopharmaceuticals Ahead of 2025 ASCO Meeting - Nasdaq
Finanzdaten der Perspective Therapeutics Inc-Aktie (CATX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Perspective Therapeutics Inc-Aktie (CATX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Spoor Johan M. | Chief Executive Officer |
Mar 28 '25 |
Buy |
2.21 |
4,650 |
10,288 |
4,650 |
| Williamson Robert F III | Director |
Mar 31 '25 |
Buy |
2.14 |
38,145 |
81,775 |
108,982 |
| Williamson Robert F III | Director |
Mar 28 '25 |
Buy |
2.27 |
22,192 |
50,376 |
70,837 |
| Graham Juan | Chief Financial Officer |
Mar 28 '25 |
Buy |
2.25 |
33,333 |
74,946 |
35,354 |
| Woods Lori A | Director |
Mar 31 '25 |
Buy |
2.13 |
23,475 |
49,999 |
183,460 |
| HENSON HEIDI | Director |
Dec 04 '24 |
Buy |
3.85 |
25,975 |
100,004 |
25,975 |
| Spoor Johan M. | CEO |
Dec 04 '24 |
Buy |
3.77 |
8,000 |
30,132 |
36,257 |
| Williamson Robert F III | Director |
Nov 25 '24 |
Buy |
3.64 |
6,266 |
22,814 |
430,058 |
| Hunt Jonathan Robert | Chief Financial Officer |
Nov 25 '24 |
Buy |
3.82 |
12,829 |
48,974 |
48,800 |
| Spoor Johan M. | CEO |
Nov 25 '24 |
Buy |
3.78 |
14,500 |
54,868 |
152,072 |
0.54%
1.82%
Kapitalisierung:
|
Volumen (24h):